HC Wainwright Forecasts OTCMKTS:BPMUF FY2026 Earnings

Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – Research analysts at HC Wainwright issued their FY2026 earnings estimates for Basilea Pharmaceutica in a research note issued to investors on Friday, November 13th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn $8.49 per share for the year.

Basilea Pharmaceutica Price Performance

Shares of OTCMKTS:BPMUF opened at $84.00 on Tuesday. Basilea Pharmaceutica has a 12 month low of $59.29 and a 12 month high of $84.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 5.97 and a current ratio of 6.60. The company’s fifty day simple moving average is $77.28 and its 200 day simple moving average is $70.05.

About Basilea Pharmaceutica

(Get Free Report)

Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.

Featured Stories

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.